Institut Pasteur has launched the ACT-CHIK project with €15.3 million in funding to accelerate clinical trials and establish local manufacturing for a chikungunya vaccine in Africa. The initiative will conduct Phase Ib/III trials in Rwanda, Kenya, Nigeria, and Senegal while facilitating the transfer of measles-virus-based vaccine technology to the Institut Pasteur de Dakar. This development is a critical step toward the African Union's goal of producing 60% of the continent's vaccine needs locally by 2040, significantly enhancing regional pandemic preparedness.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.
11
Tags
Ali NematiWritten by Ali
